Abbott Laboratories Aktie News

Abbott Laboratories is acquiring Exact Sciences, in a move that will help bolster its diagnostics business. Abbott should expand the reach of Exact Sciences' key products and fuel its innovative engine.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is s...

Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of Exact Sciences will receive $105.00 in cash for each share of...

These two medical device makers have seen huge success in their areas of specialty. DexCom has a profitable and growing CGM business, and its addressable market is expanding.

Abbott and Medtronic are innovative healthcare leaders that generate consistent revenue and profits. They also have attractive long-term prospects and have consistently raised their dividend payouts.

Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion. Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high...

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.